BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
26.00
-2.00 (-7.14%)
Last updated: Aug 12, 2025
-27.78%
Market Cap 146.75M
Revenue (ttm) 1.21M
Net Income (ttm) -18.72M
Shares Out 5.82M
EPS (ttm) -5.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,076
Average Volume 3,021
Open 28.40
Previous Close 28.00
Day's Range 25.80 - 28.40
52-Week Range 26.00 - 37.00
Beta n/a
RSI 19.90
Earnings Date n/a

About BioVersys AG

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 27
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.